Im

	E.	D'E	188°1.4	
2	JUL	1 9 2	007 کار (کیم	
1 Total	TET	ADEM	APPA OP	

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

3+5

Application Number 10/510,903

Filing Date October 8, 2004

First Named Inventor Hitoshi and Jenkins

Art Unit 1609

Examiner Name Meera Natarajan

Attorney Docket Number 021044-003310US

Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please identify Extension of Time Request **Terminal Disclaimer** below): copy of EP Search, 4 refs., Return Postcard **Express Abandonment Request** Request for Refund Information Disclosure Statement CD, Number of CD(s) Landscape Table on CD The Commissioner is authorized to charge any additional fees to Deposit Remarks Certified Copy of Priority Account 20-1430. Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Townsend and Townsend and Crew LLP Signature Printed name Beth L. Kelly Reg. No. Date 51,868 CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service wire postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alex 22313-1450 on the date shown below.	th sufficient kandria, VA

Typed or printed name

Julie Taylor Clough

Date

Date

I hereby certify that this correspondence is being deposited with the United
States Postal Service as first class mail in an envelope addressed to Attorney Docket No.: 021044-003310US
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
On
TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HITOSHI and JENKINS

Application No.: 10/510,903

Filed: October 8, 2004

For: METHODS OF ASSAYING FOR

CELL CYCLE MODULATORS

Confirmation No.: 1730

Examiner: Meera Natarajan

Art Unit: 1609

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER

37 CFR §1.97 and §1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A&08B are being called to the attention of the Examiner. Copies of the references, in compliance with the requirements of 37 CFR §1.98(a)(2), are enclosed.

Also enclosed is a copy of the Search/Examination report corresponding to the European application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Application No.: 10/510,903

Page 2

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

CERTIFICATION

I hereby certify that each item of information contained in this Information

Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Beth L. Kelly

Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

BLK:jtc

61070870 v1

JUL 1 9 2007

Substitute for form 1449A&B/PTO Complete if Known Application Number 10/510,903 **INFORMATION DISCLOSURE** Filing Date October 8, 2004 STATEMENT BY APPLICANT First Named Inventor Art Unit 1609 (Use as many sheets as necessary) Examiner Name Meera Natarajan 1 Attorney Docket Number 1 021044-003310US Sheet

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	US-				
	AB	US-				
	AC	US-				
	AD	US-				

FOREIGN PATENT DOCUMENTS								
Examiner Cite Initials* No.1		Foreign Patent Document			Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
	NO.	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T⁰
	AE	wo	02/44340	A2	06-06-2002	HYSEQ, INC.		
	AF	DE	19904650	A1	08-17-2000	Multigene Biotech GmBH		
***************************************	AG			4.1. (a) 1. (a)				

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	АН	GARCIA-HIGUERA, Irene, et al., "The Fanconi anemia proteins FANCA and FANCG stabilize each other and promote nuclear accumulation of the Fanconi anemia complex;" November 1, 2000; Blood; Vol. 96; No. 9; pp. 3224-3230.			
	ΑI	OTSUKI, Tetsuya, et al., "Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex;" 2001; <u>Human Molecular Genetics</u> ; Vol. 10; No. 23; pp. 2651-2660.			
	AJ				
	AK				

	I I	I
Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include conv of this form with next communication to applicant

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.